Answers are grounded in this paper and cite their sources.
Intratumoral bacteria are increasingly recognized as important regulators of tumor progression, immune suppression, and metastasis, whereas current therapeutic strategies remain insufficient to address the coupled tumor–bacteria microenvironment. Here, we report a multicyclic catalytic network (VBC-Net) that integrates alkaline polyoxovanadate with a Bi2WO6–CuSx p–n heterojunction for coordinated antitumor–antibacterial immunotherapy. Unlike conventional single-mechanism nanozymes, VBC-Net establishes interconnected catalytic cycles that sustain ROS amplification, oxygen activation, and glutathione depletion, thereby converting transient catalytic activity into persistent oxidative stress. Simultaneously, the alkaline microenvironment and Bi-associated interference with respiratory-chain-related processes may contribute to metabolic perturbation, coupling oxidative stress with metabolic disruption. VBC-Net is further associated with dendritic-cell maturation, enhanced T-cell infiltration, and pro-inflammatory immune modulation, suggesting remodeling of the tumor–bacteria–immune microenvironment. In murine 4T1 tumor and MRSA-infected models, VBC-Net achieves pronounced tumor suppression, bacterial clearance, reduced metastatic progression, and accelerated wound healing with good biocompatibility. This work establishes a multicyclic catalytic strategy for targeting complex tumor-associated ecosystems and provides a promising framework for antitumor–antibacterial therapy.
No takes yet. Share an insight, caveat, or question.
Ban et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: